NO971473L - TagA genet og fremgangsmåte for påvisning av predisponering for peptisk ulcerasjon og gastrisk karcinom - Google Patents

TagA genet og fremgangsmåte for påvisning av predisponering for peptisk ulcerasjon og gastrisk karcinom

Info

Publication number
NO971473L
NO971473L NO971473A NO971473A NO971473L NO 971473 L NO971473 L NO 971473L NO 971473 A NO971473 A NO 971473A NO 971473 A NO971473 A NO 971473A NO 971473 L NO971473 L NO 971473L
Authority
NO
Norway
Prior art keywords
antigen
taga
peptic ulceration
gastric carcinoma
predisposition
Prior art date
Application number
NO971473A
Other languages
English (en)
Norwegian (no)
Other versions
NO971473D0 (no
Inventor
Timothy L Cover
Martin J Blaser
Harry Kleanthous
Murali K R Tummuru
Original Assignee
Univ Vanderbilt
Oravax Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Vanderbilt, Oravax Inc filed Critical Univ Vanderbilt
Publication of NO971473D0 publication Critical patent/NO971473D0/no
Publication of NO971473L publication Critical patent/NO971473L/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/205—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Campylobacter (G)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6888—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for detection or identification of organisms
    • C12Q1/689—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for detection or identification of organisms for bacteria
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • G01N33/56911—Bacteria
    • G01N33/56922—Campylobacter
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57407—Specifically defined cancers
    • G01N33/57446—Specifically defined cancers of stomach or intestine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/195—Assays involving biological materials from specific organisms or of a specific nature from bacteria
    • G01N2333/205—Assays involving biological materials from specific organisms or of a specific nature from bacteria from Campylobacter (G)
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2469/00—Immunoassays for the detection of microorganisms
    • G01N2469/20—Detection of antibodies in sample from host which are directed against antigens from microorganisms
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/06—Gastro-intestinal diseases
    • G01N2800/062—Gastritis or peptic ulcer disease
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/50—Determining the risk of developing a disease

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Analytical Chemistry (AREA)
  • Molecular Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Pathology (AREA)
  • Medicinal Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Hematology (AREA)
  • Biophysics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Food Science & Technology (AREA)
  • Oncology (AREA)
  • Cell Biology (AREA)
  • Hospice & Palliative Care (AREA)
  • General Physics & Mathematics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Virology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Gastroenterology & Hepatology (AREA)
NO971473A 1994-09-30 1997-04-01 TagA genet og fremgangsmåte for påvisning av predisponering for peptisk ulcerasjon og gastrisk karcinom NO971473L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US08/316,397 US5733740A (en) 1992-10-13 1994-09-30 Taga gene and methods for detecting predisposition to peptic ulceration and gastric carcinoma
PCT/US1995/012669 WO1996010639A2 (fr) 1994-09-30 1995-09-29 GENE tagA ET PROCEDES DE DETECTION D'UNE PREDISPOSITION AUX ULCERES GASTRODUODENAUX ET AUX CARCINOMES GASTRIQUES

Publications (2)

Publication Number Publication Date
NO971473D0 NO971473D0 (no) 1997-04-01
NO971473L true NO971473L (no) 1997-05-29

Family

ID=23228874

Family Applications (1)

Application Number Title Priority Date Filing Date
NO971473A NO971473L (no) 1994-09-30 1997-04-01 TagA genet og fremgangsmåte for påvisning av predisponering for peptisk ulcerasjon og gastrisk karcinom

Country Status (16)

Country Link
US (3) US5733740A (fr)
EP (1) EP0783579B1 (fr)
JP (1) JPH10509864A (fr)
CN (1) CN1166858A (fr)
AT (1) ATE276365T1 (fr)
CA (1) CA2201353A1 (fr)
CZ (1) CZ96697A3 (fr)
DE (1) DE69533514T2 (fr)
ES (1) ES2231792T3 (fr)
FI (1) FI971326A (fr)
HU (1) HUT76730A (fr)
MX (1) MX9702335A (fr)
NO (1) NO971473L (fr)
NZ (1) NZ295297A (fr)
PL (1) PL319441A1 (fr)
WO (1) WO1996010639A2 (fr)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1993018150A1 (fr) * 1992-03-02 1993-09-16 Biocine S.P.A. Proteines d'helicobacter pylori utiles pour des vaccins et des diagnostics
US7141244B1 (en) * 1992-03-02 2006-11-28 Chiron Srl Helicobacter pylori proteins useful for vaccines and diagnostics
US5733740A (en) * 1992-10-13 1998-03-31 Vanderbilt University Taga gene and methods for detecting predisposition to peptic ulceration and gastric carcinoma
US6290962B1 (en) 1992-11-03 2001-09-18 Oravax, Inc. Urease-based vaccine and treatment for helicobacter infection
US5972336A (en) * 1992-11-03 1999-10-26 Oravax Merieux Co. Urease-based vaccine against helicobacter infection
CA2194237A1 (fr) * 1994-07-01 1996-01-18 Dermot Kelleher Preparation a base de proteine antigene d'helicobacter pylori et dosage immunologique
GB2324093A (en) * 1996-01-04 1998-10-14 Rican Limited Helicobacter pylori bacterioferritin
WO1998021225A1 (fr) * 1996-11-14 1998-05-22 Merieux Oravax Polypeptides helicobacter et molecules de polynucleotides correspondantes
US6902903B1 (en) * 1996-12-19 2005-06-07 Chiron Corporation Helicobacter pylori diagnostics
TWI237695B (en) * 1999-12-14 2005-08-11 Joy Biomedical Corp Helicobacter pylori antigens in blood
EP1423142A1 (fr) * 2001-08-31 2004-06-02 Chiron SRL. Vaccination contre l'helicobacter pylori avec une combinaison de proteines caga, vaca et nap
FI118061B (fi) * 2001-09-24 2007-06-15 Beanor Oy Menetelmä ja bioanturi analyysiä varten
WO2003060121A2 (fr) * 2001-12-21 2003-07-24 Diadexus, Inc. Compositions et procedes relatifs a des proteines et a des genes gastriques specifiques
FI115166B (fi) * 2001-12-31 2005-03-15 Biofons Oy Diagnostisia menetelmiä
AU2002250779A1 (en) * 2002-03-26 2003-10-08 Peking University School Of Oncology A method of inspecting the genetic susceptibility of h.pylori related gastric carcinoma and the use of it
TWI276631B (en) * 2002-09-12 2007-03-21 Avanir Pharmaceuticals Phenyl-aza-benzimidazole compounds for modulating IgE and inhibiting cellular proliferation
US20040142379A1 (en) 2003-01-16 2004-07-22 Carlsberg Research Laboratory Affinity fishing for ligands and proteins receptors
US7968324B2 (en) 2004-08-13 2011-06-28 Barry J Marshall Helicobacter system and uses thereof
US8029777B2 (en) 2004-08-13 2011-10-04 Marshall Barry J Helicobacter system and uses thereof
US9568471B2 (en) * 2005-01-25 2017-02-14 The Johns Hopkins University Plasmodium diagnostic assay device

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5262156A (en) * 1991-08-12 1993-11-16 Hycor Biomedical, Inc. Antigenic compositions and their use for the detection of Helicobacter pylori
WO1993018150A1 (fr) * 1992-03-02 1993-09-16 Biocine S.P.A. Proteines d'helicobacter pylori utiles pour des vaccins et des diagnostics
US5733740A (en) * 1992-10-13 1998-03-31 Vanderbilt University Taga gene and methods for detecting predisposition to peptic ulceration and gastric carcinoma
US5403924A (en) * 1992-10-13 1995-04-04 Vanderbilt University Taga gene and methods for detecting predisposition to peptic ulceration

Also Published As

Publication number Publication date
FI971326A0 (fi) 1997-03-27
EP0783579B1 (fr) 2004-09-15
NZ295297A (en) 1999-03-29
FI971326A (fi) 1997-05-27
MX9702335A (es) 1997-10-31
EP0783579A2 (fr) 1997-07-16
CN1166858A (zh) 1997-12-03
PL319441A1 (en) 1997-08-04
AU703075B2 (en) 1999-03-11
DE69533514D1 (de) 2004-10-21
WO1996010639A2 (fr) 1996-04-11
WO1996010639A3 (fr) 1996-05-17
US5733740A (en) 1998-03-31
US5876943A (en) 1999-03-02
HUT76730A (en) 1997-11-28
US6153390A (en) 2000-11-28
NO971473D0 (no) 1997-04-01
AU3858995A (en) 1996-04-26
DE69533514T2 (de) 2005-09-15
ES2231792T3 (es) 2005-05-16
CZ96697A3 (en) 1997-10-15
CA2201353A1 (fr) 1996-04-11
JPH10509864A (ja) 1998-09-29
ATE276365T1 (de) 2004-10-15

Similar Documents

Publication Publication Date Title
NO971473L (no) TagA genet og fremgangsmåte for påvisning av predisponering for peptisk ulcerasjon og gastrisk karcinom
Byerlee Brittle‐ductile transition in rocks
ATE152524T1 (de) Antigene zusammensetzungen aus fragmenten von campylobacter pylori und verfahren zu ihrer herstellung und verwendung
DK0677533T3 (da) Antistoffer mod epitoper med homologi til selv-antigener, fremgangsmåder til fremstilling og anvendelser deraf
ATE328280T1 (de) Verfahren und zusammensetzungen zur karzinomdiagnose
DE3579841D1 (de) Multisites immunometrisches testverfahren.
HUT74352A (en) Methods for producing probes, which are able to hibridre with dna molecules coping glukagon receptor and of monoclonal antibodies against thereof
Asaduzzaman et al. The major subunit of the toxin-coregulated pilus TcpA induces mucosal and systemic immunoglobulin A immune responses in patients with cholera caused by Vibrio cholerae O1 and O139
NO962084L (no) DNA sekvens som koder for en BMP reseptor
NO161287C (no) Homogen immunologisk analysemetode, reagensmidler og proeveinnretning for bruk ved immunoanalysebestemmelse.
FI990992A0 (fi) Menetelmä peptisen haavan riskin määrittämiseksi
Uibo et al. Association of Helicobacter pylori and gastric autoimmunity: a population-based study
Kawamoto et al. Purification and immunochemical characterization of a recombinant outer membrane protein from Bacteroides gingivalis.
WO2001084146A3 (fr) Biocapteur multiplex sensible a spectrometrie de masse base sur l'immuno-pcr
ES483606A1 (es) Metodo y su correspondiente kit de prueba para la deteccion-y-o determinacion de una inmunoglobulina especifica antige- nica.
KR930016439A (ko) 시이엔피-비(cenp-b)항원 결정부
DK0991945T3 (da) Fremgangsmåde til identifikation af tumor-antigener med antistoffer i serum
BRPI0414784B8 (pt) método e dispositivo para detectar quantidades muito pequenas de partículas
Matsuo et al. Novel CagA ELISA exhibits enhanced sensitivity of Helicobacter pylori CagA antibody
Yilmaz et al. Detection of H pylori infection by ELISA and Western blot techniques and evaluation of anti CagA seropositivity in adult Turkish dyspeptic patients
Nardone et al. Cirrhosis negatively affects the efficiency of serologic diagnosis of Helicobacter pylori infection.
Suzuki et al. Catalase, a specific antigen in the feces of human subjects infected with Helicobacter pylori
KR860001189A (ko) 재조합인자 ⅷ-r의 제조방법
DE50210523D1 (de) Verfahren zur identifizierung von zielepitopen der t-zell-vermittelten immunantwort und zum nachweis epitop-spezifischer t-zellen
WO2021101452A3 (fr) Procédé et système d'identification et de validation d'antigènes candidats partagés et de paires de lymphocytes t spécifiques d'un antigène partagé

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application